About: Ipamorelin

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue. It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from . Ipamorelin was originally developed by Novo Nordisk, and was investigated in phase II clinical trials by for the treatment of postoperative ileus, but was discontinued due to lack of efficacy. Ipamorelin has been used by athletes as a performance enhancing drug.

thumbnail
Property Value
dbo:abstract
  • Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue. It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from . Ipamorelin significantly increases plasma growth hormone (GH) levels in both animals and humans. In addition, ipamorelin stimulates body weight gain in animals. Like pralmorelin and GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels. However, unlike pralmorelin (GHRP-2) and GHRP-6, but similarly to growth hormone-releasing hormone (GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH) or cortisol, and is highly selective for inducing the secretion only of GH. Ipamorelin was originally developed by Novo Nordisk, and was investigated in phase II clinical trials by for the treatment of postoperative ileus, but was discontinued due to lack of efficacy. Ipamorelin has been used by athletes as a performance enhancing drug. (en)
dbo:casNumber
  • 170851-70-4
dbo:fdaUniiCode
  • Y9M3S784Z6
dbo:pubchem
  • 20754357
dbo:thumbnail
dbo:wikiPageID
  • 46948672 (xsd:integer)
dbo:wikiPageLength
  • 7295 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1120771287 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • None (en)
dbp:c
  • 38 (xsd:integer)
dbp:casNumber
  • 170851 (xsd:integer)
dbp:chemspiderid
  • 8007390 (xsd:integer)
dbp:eliminationHalfLife
  • 7200.0
dbp:h
  • 49 (xsd:integer)
dbp:iupacName
  • -6 (xsd:integer)
dbp:n
  • 9 (xsd:integer)
dbp:o
  • 5 (xsd:integer)
dbp:pubchem
  • 20754357 (xsd:integer)
dbp:routesOfAdministration
dbp:smiles
  • CCN (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • NEHWBYHLYZGBNO-BVEPWEIPSA-N (en)
dbp:unii
  • Y9M3S784Z6 (en)
dbp:width
  • 250 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue. It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from . Ipamorelin was originally developed by Novo Nordisk, and was investigated in phase II clinical trials by for the treatment of postoperative ileus, but was discontinued due to lack of efficacy. Ipamorelin has been used by athletes as a performance enhancing drug. (en)
rdfs:label
  • Ipamorelin (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License